Hoppa till innehåll
/Kostnader och sjukdomsbörda

Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study

Norlin J M, Hjalte F, Kruse C, Dodel R, Rosqvist K, Odin P

People with late-stage PD is a vulnerable patient group that is costly to society and their HRQoL impairment is immense. This is shown in this article in Parkinson’s disease.

Few studies have investigated the health-related quality of life (HRQoL), resource use and costs in patients with late-stage Parkinson’s disease (PD), and data from the Swedish setting are scarce.

First, we analyse the HRQoL in late-stage PD in Sweden. Second, we analyse the resource use and costs per severity level. Third, we analyse the relationship between costs and physician- and patient reported-outcome measures.

Materials and methods
The study was based on Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study. The costs of healthcare contacts, drugs, formal and informal care, and productivity loss were collected over three months. Assessments at baseline were used for outcomes (EQ-5D, Hoehn and Yahr (H&Y), Schwab and England Scale, Unified Parkinson’s Disease Rating Scale subscales (UPDRS) and Non-Motor Symptoms Scale (NMSS)). Costs were estimated in € 2016.

In total, 106 patients were included. The mean EQ-5D score in the total group was 0.24 (±0.33). The mean total cost excluding informal care per patient in the three-month period was approximately €14,097 (BCa 95% CI €12,007 and €16,039). Professional care accounted for the largest share (75 percent) of the total costs. The EQ-5D, H&Y, Schwab and England Scale, and NMSS were statistically significant predicting factors for total costs.

Patients with late-stage PD are a vulnerable patient group that is costly to society and the impairment in patients’ HRQoL is immense. Thus, healthcare decision-makers should optimize the organization and provision of healthcare for these patients.

Read more and download the article

If you would like to know more about our research in Parkinson’s disease, don’t hesitate to contact Frida Hjalte

Acta Neurologica Scandinavica, 2022;145(6):743-752)
DOI: 10.1111/ane.13611